Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, Randomized, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of MT-2766 in Japanese Adults (COVID-19)

NCT05065619 is registered in ClinicalTrials.gov with Medicago as lead sponsor.

NCT NCT05065619
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05065619 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, Randomized, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of MT-2766 in Japanese Adults (COVID-19)
Lead sponsor
Medicago
Phase
Phase 1/2
Overall status
Terminated
Start date
October 2, 2021
Completion date
January 29, 2023
Enrollment
128 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

sars-cov-2 infection